SAT-568 - Early-Phase Clinical Evaluation Of GNTI-122, An Engineered Regulatory T Cell Therapy, In Recent-Onset Type 1 Diabetes

Abstract Poster Presenter(s)

• GU

  Gene Uenishi, PhD

  Associate Director
  GentiBio
  Cambridge, Massachusetts, United States

Co-Author(s)

• KN

  Kristin M. Neff, MS

  Vice President
  GentiBio
  Cambridge, Massachusetts, United States
• DG

  Dalia Gaddis, PhD

  Principal Scientist
  GentiBio
  Cambridge, Massachusetts, United States
• VD

  Victoria L. DeVault-Nelson, PhD

  Associate Director
  GentiBio
  Cambridge, Massachusetts, United States
• AM

  Abigail Meiners, BS

  GentiBio
  Seattle, Washington, United States
• CK

  Christine Kotynski, BS

  GentiBio
  Cambridge, Massachusetts, United States
• SY

  Soo Jung Yang, PhD

  Benaroya Research Institute
  Seattle, Washington, United States
• MR

  Marko Repic, PhD

  Director
  GentiBio, Inc
  Cambridge, Massachusetts, United States
• JB

  Jane H. Buckner, MD

  Member
  Benaroya Research Institute
  Seattle, Washington, United States
• TC

  Tiffany Chen, PhD

  Vice President
  GentiBio, Inc
  Cambridge, Massachusetts, United States
• BC

  Brian Christin, BS

  Senior Director
  GentiBio
  Seattle, Washington, United States
• TW

  Tom Wickham, PhD

  Chief Scientific Officer
  GentiBio, Inc
  Cambridge, Massachusetts, United States
• CP

  Chandra Patel, PhD

  Vice President
  GentiBio, Inc
  Cambridge, Massachusetts, United States

Senior Author/Primary Investigator(s)

• MB

  Mark A. Bach, MD, PhD

  Chief Medical Officer
  GentiBio, Inc
  Cambridge, Massachusetts, United States